A soluble-phase proinsulin assay has been developed which does net require solid-phase antibody-binding. A human proinsulin standard curve is prepared in insulin-free and proinsulin-free plasma for comparison with unknown plasma samples. Proinsulin and insulin <Ire bound with excess anti-insulin antiserum, and free C-peptide is removed by charcoal adsorption. The supernatant is then assayed using a routine C-peptide radioimmunoassay which utilises anti-Cpeptide antiserum. The sensitivity of the assay (2 standard deviations above zero) is 9 pmol/L using 200 J.lL plasma sample. The assay is free from insulin cross-reactivity
up to tOO mUlL and C-peptide up to 200()pmollL. Between-assay CY is 13'Yo at 100 pmol/L. The assay has been used in subjects with hypoglycaemia of various aetiologies and has shown that a raised plasma proinsulin in the presence of hypoglycaemia can occur in sulphonylurea-induced and reactive hypoglycaemia as well as in insulinomas. After hyperglycaemic clamps at 7·5. J() and 15 mmol/L glucose, type II diabetics both on and off sulphonylurea. were found to have lower proinsulin concentrations compared with normal subjects. commensurate with the diabetics' lower insulin responses.
Proinsulin (PI) is the precursor of insulin in the 13-cells. I Most is converted to insulin in the flcell granules, but some proinsulin, and intermediates of proinsulin conversion, have been identified'': 3 and are secreted.
Plasma PI concentrations are higher in Type II diabetic subjects," and in patients with insulin-secreting tumours of the pancreas' than in normal subjects. There is a need for a fast and straightforward assay that can be set up in routine immunoassay laboratories; for example, a raised plasma proinsulin concentration can be very helpful in the diagnosis of insulinomas. Also, since the insulin moiety of proinsulin is recognised by insulin antibodies. measurements of plasma immuno-reactive insulin (lRI) represent the sum of proinsulin and insulin immuno-reactivity," a potentially confounding influence on assessing insulin concentrations. The cross-reactivity between insulin and proinsulin is not necessarily the same for the two molecules and most specific Correspondence 
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proinsulin assays which separate these components are too complex for routine use. In addition, proinsulin is beginning to be used clinically as a long-acting stable insulin.
We describe a soluble-phase method whereby a guinea-pig anti-insulin antiserum is used to bind insulin and proinsulin, and free C-peptide is then removed by charcoal. The bound proinsulin of the supernatant is then measured by a routine Cvpeptide radioimmunoassay. Proinsulin, now available in pure form from recombinant DNA techniques (Eli Lilly; see Table I ). can be used to establish a standard curve.
Materials and methods

PRINCIPl.E 01' THE I'ROINSUI.IN ASSAY
The principle of the assay is shown in Fig. I , and the reagents are specified in Table I . Plasma samples (200 J.lL) contain insulin, proinsulin and C-peptide in unknown quantities. The first step is the use of a specific antiserum to insulin raised in guinea-pigs" (Table I) . which binds insulin and the insulin moiety of proinsulin. Insulin anti-serum is added to all Reoresent.tion 0' Proinsulin Assay tubes in the assay including those of the standard curve. After 4 h incubation at4"C the unbound tree Cspeptidc is removed from the plasma by activated charcoal which absorbs low molecular weight polypeptides. but leaves immunoglobulins in solution. Charcoal (Norit O-L. BDII; Table I ) is added and mixed. and 15 min later the sample is centrifuged (MSE Mistral 6L at 21KIO K; MSE. Crawley. Sussex. UK). and the supernatant drawn off with a pasteur pipette into a separate tube. A routine disequilibrium assay is now used to detect the Cspeptide moiety of proinsulin. Anti-C-peptide antiserum with a high cross-reactivity between C-peptide and immunoglobulin-bound proinsulin is mixed with the supernatant (exept in those tubes used for measuring non-specific binding). and after 24 h incubation at 4"C. radiolabelled C-peptide tracer is added. Activated charcoal (Norit O-L) is added 24 h later. This adsorbs the remaining free labelled C-peptide. After centrifugation the supernatant . using linear-Iogit transforms to obtain linear regression on the C-peptide assay (r typically 0·l)l)8). The sensitivity of the assay was calculated as +2 standard deviations (SO) of % bound at zero added proinsulin when read off the standard curve.
OTH ER ASSA vs
Insulin was measured by radioimmunoassay using antiserum 'GPLL' and charcoal phase separation using the method of Albano et al,' (CV: II %). C-peptide was assayed using antiserum MI230 by a similar charcoal-phase separation method" (CV: 4·5'Yo). Plasma glucose was estimated by a glucose oxidase method in a semi-automated system (Pye Unicam ACI Pye Unicam Ltd. Cambridge. UK; CV: 1,45%).
PROINSULIN ASSAV VERIFICATION
Antibody binding of proinsulin and insulin
The assay method depended on the binding of proinsulin and insulin by a specific insulinbinding antiserum which leaves C-peptide unbound. The time required for the first incubation depended on the antibody. its concentration and the temperature. 'GPLL' anti-insulin antibody bound proinsulin rapidly at 4°C. with no further significant binding occurring after 12 h. For faster assays 4 h was sufficient to ensure nearly-complete binding.
Relatively high concentrations of anti-insulin antiserum were required to ensure that proinsulin was bound and maintained in the solublephase and was not removed by charcoal. However. too high a concentration of insulin antiserum (concentrations greater than 118000) lowered the affinity of proinsulin for C-peptide antiserum. perhaps by interference between binding sites. If the first antiserum concentration was too low. then proinsulin and insulin competed for available antibody. and high insulin concentrations could leave some proinsulin unbound to be adsorbed on the charcoal. The competitive interference of insulin with the proinsulin measurement was assessed for five dilutions of insulin antiserum between 1/8000 and 1/400, at 250. 500 and 1000 pmol/mL proinsulin in the presence of 10. 50 and 100 mUlL insulin. The data are shown in Fig. 2 . as the change in binding with increasing insulin concentration. Using GPLL diluted 1/400 there was no significant change in the proinsulin binding at any ofthe three insulin concentrations. The proinsulin-antibody complex did not precipitate. With this antiserum, insulin and proinsulin reacted equally and linearly up to 350 prnol/L, and proinsulin could be regarded Less than 15 mgltube charcoal did not adsorb high levels of C-peptide and we routinely used 20 mgltube which reliably removed 2000 pmoll L C-peptide from the soluble-phase. C-peptide (2000 pmoVL) added to plasma samples in the standard curve did not affect proinsulin results ( Fig. 3 ). Insulin concentrations only affected the assay by inhibiting the initial antibody binding of proinsulin, but cross-reactivity up to insulin values >100 mUlL was eliminated when the antibody concentration wassufficiently high. Figure 3shows the lack of effect of added Cpeptide or insulin on measured proinsulin.
ASSAY SENSITIVITY AND AFFINITY OF C-PEPTI DE A NTISERU M
The sensitivity of the soluble-phase proinsulin assay was dependent upon the affinity of the Cpeptide antiserum for proinsulin ( Fig. 4) . The cross-reactivity of proinsulin with different antiserum varied, e.g. MI230 cross-reacted only about II % with proinsulin" but the affinity was found to be enhanced by the prior binding of the proinsulin with insulin antibody, so that binding increased by SO'Yo at 250 pmol/L proinsulin. The sensitivity ofthe assay was9 pmol/L using M1219 antiserum or 15pmol/L with M1230antiserum (2 SD from zero, n= 10). The binding curve was linearised using a linear (proinsulin):logit (% bound) transform. The coefficient of variation within-assay was 13°1.. at 250 pmol/L, and the intra-assay coefficient of variation was II % using the method of duplicates.
PROINSULIN STANDARDS
There were no significant differences between the immunoreactivities of biosynthetic (Eli Lilly) and pancreatic extracted (Novo) proinsulin standards in this assay.
RECOVERY ANI> DILUTION
On addition of proinsulin to three plasma samples range 240-690 pmollL proinsulin, the recovery of 200,500 and lOW pmol/L standards was 101 % (range 90-115), 92% (range 86-104) and 101 ' Yo (range 98-1(6), respectively. Dilution of a plasma sample. containing 350 pmol/Lproinsulin, to50%,25% and 12·5% using proinsulin-free plasma yielded parallel log hormone concentration curves with assay results of 47%,24% and 16%, respectively.
STORAGE-QUALITY CONTROL
Plasma samples were measured over time intervals of 5-9 months, during an 18-month period, in 23 assays. The mean, SD and coefficient of variation (CV), for each of the samples are given in Table 2 .
ASSESSMENT OF PLASMA PROtNSULIN
CONCENTRATIONS IN RELATION TO
RESULTS FROM ROUTINE C-PEPTIDE AND
INSULIN RADIOIMMUNOASSAY
Proinsulin was assayed for cross-reactivity in insulin and C-peptide assays and the results shown in Fig. 5 . The cross-reactivity of proinsulin in the C-peptide assay with antiserum was less than 25% and the cross-reactivity of proinsulin in the insulin assay with antiserum G PLL was nearly 100% below 200 pmol/L. The degree to which proinsulin cross-reacted in the insulin and Cpeptide assays was not altered by physiological levels of insulin ( Fig. 6 ) or C-peptide ( Fig. 7) . Consequently, using our assays. measured plasma proinsulin concentrations could be subtracted from immuno-reactive insulin and immuno-reactive C-peptide concentrations to determine separate insulin, C-peptide and proinsulin concentrations. Hypoglycaemia Subjects with hypoglycaemia from six differing aetiologies were studied. These were: I Nine subjects with insulinomas (surgically proven in eight). 2 Three subjects (age 2X-411 years) who took 3·5 mg rapid-acting glibenclamide (Hoechst UK Ltd .. Hounslow, Middlesex. UK) after an overnight fast. and who became hypoglycaernic within 411 min. We have termed this 'acute' hypoglycaemia. 3 One patient who took an overdose of sulphonylurea. We have termed this 'sub-acute' hypoglycaemia. 4 Severe reactive hypoglycaemia following an intravenous glucose tolerance test of ()'2 glkg glucose in an otherwise fit girl of 28-5 A 27-year-old female insulin-dependent diabetic who tried to commit suicide by administering insulin to herself while on a metabolic ward. 6 Twelve normal subjects in the fasting state.
Hyperglycaemia
Plasma proinsulin concentrations were measured in normal and diabetic subjects in whom hyperglycacmia was established using a glucose clamp method. Five NIDD and six non-diabetic subjects were studied: Their details have been reported elsewhere. 1111 n brief, they were studied on three separate days. A basal period of 3() min was followed by a glucose clamp at 7-5, 10 and 15 mmol/L glucose on the different days in random order; each clamp was continued for 2·5 h, and each was concluded by a 1 h clamp at 10 mmol/L. The diabetic subjects were studied both on and off gliclazide therapy.
Results
HYPOGLYCAEMIA
The amounts of immuno-reactive insulin, Cpeptide and proinsulin in subjects with clinical hypoglycaemia and control volunteers are shown in Table 3 . Subjects with insulinomas had a high proportion of immuno-reactive insulin in the form of proinsulin, and also had high concentrations of immunoreactive -C-peptide and insulin. Normal subjects consuming sulphonylureas also had high immunoreactive insulin. proinsulin and Cepeptide. but lower proinsulin content than the insulinoma patients. The subject who had a severe reactive hypoglycaemic reaction after an intravenous glucose tolerance test also had a raised proinsulin concentration. On the other hand. the factitious hypoglycaemia after taking an overdose of exogenous insulin showed immuno-reactive insulin with no proinsulin or C-peptide component.
When proinsulin was expressed as a percentage ofmeasured total insulin (I + PI). there was a statistical separation between those who had insulinomas (median 76'Yo; interquartile range 61-90%) and those who had hypoglycaemia after sulphonylureas (46-50%). but there was some overlap between the ranges.
HYPERGLYCAEMIA
The glucose clamp studies showed basal proinsulin concentrations which were similar in normal or mildly diabetic subjects (Table 4 ). Normal subjects showed progressively augmenting proinsulin production from 7·5 to to mmol to 15 mmol, clamps, having median responses of 36. 60 and 115 pmol/L, respectively (P«)'(Il). Diabetic subjects on diet alone showed consistently less stimulated proinsulin, but also showed an augmentation of response with higher PI at higher clamp levels (16. IX. 84 pmmol/L, respectively; P<O·OI). Finally, diabetic subjects on gliclazide showed no augmentation of response with higher clamp levels [15. 15.64 pmol/L, respectively, not significant]. The proinsulin response reflected the generally reduced insulin (C-peptide) secretory capacity in the diabetic subjects.
Discussion
The assay described has the advantage that it can be done with routine reagents available in any immunoassay laboratory. Like most of the described proinsulin assays. it is not sufficiently precise to assay normal fasting plasma concentrations. Nevertheless, it can be used to assay plasma values after stimuli and can also be used to help to diagnose insulinomas. The results in different hypoglycaemic states showed that the finding of a high proinsulin value during hypoglycaemia is not specific for an insulinoma, as similar raised values can be found after sulphonylurea in normal subjects and in reactive hypoglycaemia. It is therefore crucially important to have full clinical details before interpretation of a high proinsulin value during hypoglycaemia.
The plasma proinsulin concentrations were lower in type II diabetics than in normal subjects after hyperglycaemic clamps. This becomes especially important when assessing plasma insulin concentrations. and drawing conclusions about insulin resistance and f'.-cell function. A subject with a relatively high proinsulin concentration might be less resistant and have more I{-cell deficit than the IRI alone would imply.
Radioimmunoassay techniques for proinsulin have been developed using insulin antibodies covalently coupled to Sepharosc. II This method is sensitive but involves setting up a specific standard stock suspension of the covalently-bound antiserum, which in turn requires testing for its insulin-binding capacity in advance of the assay. An alternative solidphase system using polyethylene tubes coated with guinea-pig antibodies to insulin has also been described. 12 Assay sensitivity has been reported in different ways for different assays, and comparison is not easy. Thus. presentations have included standard error rather than standard deviation bars on standard curves and binding curves as a ratio of bound to zero-binding (BIB") rather than precise data. The overall sensitivity of an assay depends critically both on the steepness of the binding curve at low concentrations and the technical precision of estimation. The assay presented here has a sensitivity (±2 SO) of 9 pmol/L, which is similar to some published. more complex and time-consuming methods. I~. 14 Basal levels of PI in normal subjects have been reported in methods which have concentrated proinsulin as being between 4 and 24 prnol/L, "'. 14 Our assay cannot therefore measure basal proinsulin in all normal subjects without the use of concentration techniques. However. it can provide quantitative information after stimulation tests (e.g. hyperglycacmic clamps). and it can also be informative in situations where plasma proinsulin is raised (e.g. insulinomas).
The demonstration of linearity of crossreaction of proinsulin in our insulin and Cpeptide assays means that simple subtraction of plasma proinsulin concentrations from insulin or C-peptide concentrations is appropriate when this assay is used. This then allows a simple method for separating insulin immunoreactivity into its insulin and proinsulin.
Antibodies recognising the insulin-A-chain+ C-peptide-region or B-chain + C-peptide-region would. in theory. not cross-react with either insulin or C-peptide. Such an antibody has been described for use with an immunoassay. n but it requires I mL of sample and a concentrating procedure (ethanol precipitation of high molecular weights. and resuspension in buffer). The proinsulin assay described here has the advantage that it uses routine radioimmunoassay techniques and reagents. It is relatively easy to undertake and requires only 2(KJ IJ.L of plasma sample. The assay probably measures intact proinsulin and derivative molecules with either the A/C or B/C junctions split, as the antibodies used detect the insulin and C-peptide moieties separately. This overall immunoreactivity may be helpful if one wishes to assess the efficiency of Ii-cell conversion of proinsulin to insulin. A specific assay of proinsulin alone, which did not measure the clipped products. would underestimate the amount of proinsulin produced which was not fully converted to insulin.
